A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain

Last updated:
2026-07-25
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDING, PHASE 2 STUDY (MARS-17) OF GSK3858279 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PAIN DUE TO KNEE OSTEOARTHRITIS

Intervention/treatment:
GSK3858279
Medical condition:
OSTEOARTHRITIS OF THE KNEE
Protocol code:
209978
Control number:
273672
Status:
Closed
Approved:
April 21, 2023
Date Completed:
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT05838742
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
40 Years to 80 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
GSK Response Center
Organization
GlaxoSmithKline
Phone:
866-435-7343
Sponsor
GLAXOSMITHKLINE INC

Locations

British Columbia

GSK Investigational Site
Victoria, British Columbia, V8V 4A1

Ontario

GSK Investigational Site
Brampton, Ontario, L6T 0G1
GSK Investigational Site
Guelph, Ontario, N1H 1B1
GSK Investigational Site
Sarnia, Ontario, N7T 4X3
GSK Investigational Site
Toronto, Ontario, M5T 2S8
GSK Investigational Site
Toronto, Ontario, M9V 4B4
GSK Investigational Site
Winchester, Ontario, K0C 2K0

Quebec

GSK Investigational Site
Joliette, Quebec, J6E 6A9
GSK Investigational Site
Sherbrooke, Quebec, J1L 0H8
GSK Investigational Site
Trois-Rivières, Quebec, G9A 3X2

Results

See the results from the trial NCT05838742. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?